AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
RESEARCH TRIANGLE PARK, N.C., March 29, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at the 16th Annual Needham Healthcare Conference in New York on Tuesday, April 4, 2017 at 8:40 AM Eastern Time.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitment development activities are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
